4-(trifluoromethyl)phenethyl 4-methylbenzenesulfonate | 26416-26-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(trifluoromethyl)phenethyl 4-methylbenzenesulfonate
• 英文别名: toluene-4-sulfonic acid 2-(4-trifluoromethylphenyl)-ethyl Ester；2-(4-Trifluoromethylphenyl)ethyl p-toluenesulfonate；2-[4-(trifluoromethyl)phenyl]ethyl 4-methylbenzenesulfonate
• CAS: 26416-26-2
• 化学式: C₁₆H₁₅F₃O₃S
• 分子量: 344.355
• InChiKey: QJYJPHNLAZPGDL-UHFFFAOYSA-N

物化性质

• 沸点：
  432.8±45.0 °C(Predicted)
• 密度：
  1.301±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(trifluoromethyl)phenethyl 4-methylbenzenesulfonate 在 硫酸 、 溶剂黄146 、 三乙胺 作用下， 以 水 、 甲苯 为溶剂， 反应 18.25h， 生成 2-羟基-5-[2-[4-(三氟甲基)苯基]乙胺基]苯甲酸
  参考文献：
  名称：

  METHOD FOR PREPARING 2-HYDROXY-5-[2-(4-(TRIFLUOROMETHYLPHENYL)ETHYLAMINO)]BENZOIC ACID

  摘要：

  A method for preparing 2-hydroxy-5-[2-(4-(trifluoromethylphenyl)ethylamino)]benzoic acid is proposed. The method may include protection, condensation, and hydrolysis. By means of the screening of a hydroxyl protecting reagent for a starting material, for example, 2-(4-trifluoromethyl)phenethylalcohol and the optimization of other process parameters, the contents of meta-isomer impurities and disubstituted impurities in a target product are effectively controlled. Accordingly, the quality of the product is significantly improved, the reaction yield is also greatly improved, and the improved product quality can satisfy related requirements of preparation research.

  公开号：

  US20240051915A1
• 作为产物：
  描述：

  4-(三氟甲基)苯乙醇 生成 4-(trifluoromethyl)phenethyl 4-methylbenzenesulfonate
  参考文献：
  名称：

  Effect of solvent on .beta.-arylalkyl solvolysis

  摘要：

  DOI：

  10.1021/ja00469a040

文献信息

• N-substituted heterocyclic amines as modulators of chemokine receptor activity
  申请人：——

  公开号：US20040067935A1

  公开（公告）日：2004-04-08

  The present application describes modulators of chemokine receptors of formula (I): 1 or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.

  本申请描述了化学式(I)的趋化因子受体调节剂或其药用盐形式，可用于预防哮喘和其他过敏性疾病。
• Ｔ-형 칼슘 채널에 활성을 가지는 피롤리딘 또는 피페리딘 화합물
  申请人：KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY 한국과학기술연구원(319980077518) BRN ▼209-82-03522

  公开号：KR20200022710A

  公开（公告）日：2020-03-04

  본 발명은 Ｔ-형 칼슘 채널에 활성을 가지는 피롤리딘 또는 피페리딘 화합물에 대한 것으로, 더욱 자세하게는 본 발명에 따른 화학식 1로 표시되는 피롤리딘 또는 피페리딘 화합물은, T-형 칼슘채널에 대하여 우수한 길항작용을 가지고 있어서, 간질, 고혈압 등의 뇌질환, 협심증 등의 심장질환, 만성 통증, 신경성 통증 등의 통증질환, 또는 암과 관련 질병의 예방 또는 치료제로서 유용하게 사용될 수 있다.

  本发明涉及对T型钙通道具有活性的吡啶或哌啶化合物，更具体地说，根据本发明，化学式1所示的吡啶或哌啶化合物对T型钙通道具有优异的抑制作用，可用于治疗或预防癫痫、高血压等脑部疾病，心脏疾病如心绞痛，慢性疼痛，神经性疼痛等疼痛性疾病，以及与癌症相关的疾病。
• Synthesis and biological evaluation of pyrrolidine-based T-type calcium channel inhibitors for the treatment of neuropathic pain
  作者：Hak Kyun Yang、Woo Seung Son、Keon Seung Lim、Gun Hee Kim、Eun Jeong Lim、Changdev G. Gadhe、Jae Yeol Lee、Kyu-Sung Jeong、Sang Min Lim、Ae Nim Pae

  DOI：10.1080/14756366.2018.1513926

  日期：2018.1.1

  T-type channel inhibitors showed promising in vivo efficacy in neuropathic pain animal models and are being investigated in clinical trials. Herein we report development of novel pyrrolidine-based T-type calcium channel inhibitors by pharmacophore mapping and structural hybridisation followed by evaluation of their Cav3.1 and Cav3.2 channel inhibitory activities. Among potent inhibitors against both

  神经性疼痛的治疗是迫切的医疗需求之一，T型钙通道是神经性疼痛的有希望的治疗靶点。几种有效的T型通道抑制剂在神经性疼痛动物模型中显示出有希望的体内功效，并且正在临床试验中进行研究。在本文中，我们报告了通过药效基团定位和结构杂交，然后对其Cav3.1和Cav3.2通道抑制活性进行评估的新型基于吡咯烷的T型钙通道抑制剂的开发。根据体内药代动力学研究，在针对Cav3.1和Cav3.2通道的有效抑制剂中，一种基于体外ADME特性的有前途的化合物20n在大鼠中显示出令人满意的血浆和脑暴露。
• Pyrrolidine compounds and medicinal utilization thereof
  申请人：Mitsubishi Pharma Corporation

  公开号：US06468998B1

  公开（公告）日：2002-10-22

  The present invention provides a pyrrolidine compound of the formula (I) wherein each symbol is as defined in the specification, an optically active compound thereof and a pharmaceutically acceptable salt thereof. The present invention further provides a pharmaceutical composition containing a compound of the formula (I), an optically active compound thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive. The compound of the present invention has a serotonin 2 receptor antagonistic action along with a platelet aggregation suppressive action, a peripheral circulation improving action and a lacrimation promoting action. Therefore, the compound of the present invention can be a useful medicine showing effect against thrombotic embolism, dry eye and the like.

  本发明提供了一种式（I）的吡咯烷化合物，其中每个符号如规范中所定义，以及其光学活性化合物和药学上可接受的盐。本发明还提供了一种含有式（I）化合物、其光学活性化合物或药学上可接受的盐以及药学上可接受的添加剂的制药组合物。本发明所述化合物具有血清素2受体拮抗作用以及抑制血小板聚集、改善外周循环和促进泪液分泌的作用。因此，本发明所述化合物可以是一种有益的药物，具有对抗血栓栓塞、干眼症等疾病的作用。
• Electrochemical Nickel-Catalyzed C(sp³)–C(sp³) Cross-Coupling of Alkyl Halides with Alkyl Tosylates
  作者：Malek Y. S. Ibrahim、Graham R. Cumming、Raquel Gonzalez de Vega、Pablo Garcia-Losada、Oscar de Frutos、C. Oliver Kappe、David Cantillo

  DOI：10.1021/jacs.3c07313

  日期：2023.8.9

  nickel-catalyzed, electrochemically driven method for the coupling of alkyl bromides with alkyl tosylates. Selective cross-coupling transformations were achieved even between C(sp3)-secondary bromides and tosylates. Key to achieve high selectivity was the combination of the tosylates with sodium bromide as the supporting electrolyte, gradually generating small amounts of the more reactive bromide by substitution and

  新的C(sp 3 )–C(sp 3 )键的形成是增加分子多样性的强大合成工具，这在药物化学中备受追捧。当尝试交叉偶联类似的含 C(sp 3 )反应物时，传统的碳亲核试剂生成和更现代的交叉亲电子偶联方法通常缺乏足够的选择性。在此，我们提出了一种镍催化、电化学驱动的方法，用于烷基溴与甲苯磺酸烷基酯的偶联。甚至在C(sp 3 )-仲溴化物和甲苯磺酸盐之间也实现了选择性交叉偶联转化。实现高选择性的关键是将甲苯磺酸盐与溴化钠作为支持电解质组合，通过取代逐渐产生少量更具活性的溴化物，并确保镍催化电还原过程中的反应伙伴之一在反应过程中保持过量。该过程的很大一部分。该方法已在多种底物（> 30 种化合物）中得到证实，产率中等至良好。进一步将有机电合成的范围扩大到C(sp 3 )–C(sp 3 )交叉偶联反应预计将促进向绿色有机合成的转变，并鼓励未来创新的电化学转化。